在第三阶段试验中,Datroway延长了无资格接受免疫疗法的转移性三联阴性乳腺癌患者的生存期。 Datroway extends survival in metastatic triple-negative breast cancer patients ineligible for immunotherapy, per phase III trial.

AstraZeneca和Daichi Sankyo宣布,根据第三阶段的试验结果,Datroway显著地改善了患有三联负性乳癌、没有资格接受免疫疗法的病人的全面和无进展生存。 AstraZeneca and Daiichi Sankyo announced that Datroway significantly improved overall and progression-free survival in patients with metastatic triple-negative breast cancer who aren’t eligible for immunotherapy, based on phase III trial results. 这是这一群体中第一种显示比化疗有生存效益的治疗方法,该群体中约有70%的病人。 It is the first treatment to show a survival benefit over chemotherapy in this group, which includes about 70% of patients. 药物安全情况保持不变,公司计划向监管者提交数据,并在一次医疗会议上提出调查结果。 The drug’s safety profile remained consistent, and the companies plan to submit data to regulators and present findings at a medical meeting. Tatroway,Trop2方向的抗体药物共合体,已经获准治疗某些肺癌。 Datroway, a Trop2-directed antibody-drug conjugate, is already approved for some lung cancers.